文献速递慢性静脉疾病

人工静脉瓣与压力治疗及伤口护理治疗腹股沟下深静脉反流的成本效益

Cost-effectiveness of a prosthetic venous valve versus compression therapies and wound care for treatment of infra-inguinal deep vein reflux.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2026-06-29

本研究基于SAVVE试验数据构建半马尔可夫队列模型,评估VenoValve生物假体静脉瓣相比标准治疗用于严重腹股沟下深静脉反流患者的成本效益。结果显示VenoValve在5年内平均每患者避免2.2个溃疡,节省32,153美元,且以更低成本获得更高质量调整生命年,具有经济学优势。

要点

  • VenoValve相比标准治疗5年内平均每患者避免2.2个溃疡。
  • 每患者节省32,153美元,每避免一个溃疡节省14,779美元。
  • VenoValve为优势策略,成本更低且质量调整生命年更高。

核心结论

  • 在模型中,VenoValve为严重腹股沟下慢性静脉功能不全患者带来显著经济收益和健康结局改善。

研究设计与样本

  • 基于SAVVE前瞻性、非盲、单臂、多中心试验数据构建半马尔可夫队列模型,模拟5年临床与经济结局。

主要发现

  • VenoValve组5年内平均每患者避免2.2个溃疡。
  • 每患者节省32,153美元,每避免一个溃疡节省14,779美元。
  • 修订版静脉临床严重程度评分每变化1分的成本为4,065美元。
  • VenoValve相对于标准治疗为优势策略,即成本更低且质量调整生命年更高。
  • 单因素敏感性分析结果稳健。

关键数值与推荐

  • 模型健康状态基于修订版静脉临床严重程度评分定义。
  • 患者可能经历深静脉血栓、肺栓塞、溃疡愈合和溃疡复发。
  • 关键输入值来源于SAVVE试验和公开可得来源。

临床怎么用

  • 对于严重腹股沟下深静脉反流患者,VenoValve可能作为标准治疗之外具有成本效益的选择。

局限性

  • 模型基于单臂试验数据和公开来源,可能存在不确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with chronic venous insufficiency secondary to infra-inguinal deep vein reflux have few treatment options available to them, given the focus-to-date has been directed toward obstruction rather than reflux. The SAVVE trial was a prospective, non-blinded, single arm, multicenter study designed to assess the safety and efficacy of VenoValve, a bioprosthetic replacement venous valve that is surgically implanted into the deep venous system for treatment of patients with severe infra-inguinal deep venous reflux (Clinical, Etiological, Anatomical, and Pathophysiological classification C4b-C6). This study was designed to estimate the cost-effectiveness of VenoValve compared to the current standard of care for patients with severe infra-inguinal deep vein reflux. METHODS: A semi-Markov cohort model was developed to simulate clinical and economic outcomes among patients with deep venous chronic venous insufficiency through health states defined by revised Venous Clinical Severity Score. Patients could experience deep vein thrombosis, pulmonary embolism, ulcer healing, and ulcer recurrence. Key input values were sourced from the SAVVE trial and publicly available sources. Outcomes were compared over 5 years. RESULTS: Treatment with VenoValve resulted in an average of 2.2 ulcers avoided per-patient over 5 years. These clinical benefits translated into savings of $32,153 per patient, $14,779 per ulcer avoided, and a cost per revised Venous Clinical Severity Score point change of $4065; VenoValve was dominant relative to standard of care (ie, lower costs, higher quality-adjusted life years). Results were robust in one-way sensitivity analyses. CONCLUSIONS: In our model, VenoValve yields substantial economic benefits and improved health outcomes for patients suffering from severe infra-inguinal chronic venous insufficiency.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Benner J, Arguello R, Pappas P, et al. Cost-effectiveness of a prosthetic venous valve versus compression therapies and wound care for treatment of infra-inguinal deep vein reflux. J Vasc Surg Venous Lymphat Disord. 2026. PMID: 42372948. doi:10.1016/j.jvsv.2026.102565

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。